Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site

Valuation: Pacira BioSciences, Inc.

Capitalization 770M 733M 682M 608M 1.08B 65.24B 1.19B 8.49B 3.15B 26.75B 2.89B 2.83B 115B P/E ratio 2024 *
-8.11x
P/E ratio 2025 * 10.9x
Enterprise value 887M 844M 786M 701M 1.25B 75.17B 1.37B 9.78B 3.62B 30.83B 3.33B 3.26B 133B EV / Sales 2024 *
1.28x
EV / Sales 2025 * 1.12x
Free-Float
96.11%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-6.34%
1 week-0.60%
Current month-1.36%
1 month+0.66%
3 months+9.88%
6 months-46.00%
Current year-50.56%
More quotes
1 week
16.41
Extreme 16.41
17.94
1 month
16.00
Extreme 16
18.34
Current year
11.16
Extreme 11.164
35.95
1 year
11.16
Extreme 11.164
35.95
3 years
11.16
Extreme 11.164
82.16
5 years
11.16
Extreme 11.164
82.16
10 years
11.16
Extreme 11.164
121.95
More quotes
Director TitleAgeSince
Chief Executive Officer 56 2024-01-01
Director of Finance/CFO 56 2024-10-20
Chief Operating Officer 62 2022-05-03
Manager TitleAgeSince
Director/Board Member 65 2006-11-30
Director/Board Member 66 2011-06-01
Chairman 64 2024-01-01
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-6.34%-0.60%-40.02%-68.25%770M
+1.69%+3.04%+39.26%+231.19%732B
-0.60%+4.41%+12.14%+119.08%488B
-1.58%-1.40%-3.80%-4.40%367B
-0.15%+0.20%+26.56%+52.71%321B
+1.23%+0.23%-1.56%+38.87%258B
-0.35%+0.51%+3.05%-30.95%231B
-2.13%-1.84%+5.69%+21.99%210B
-2.51%-0.25%+2.34%+25.62%212B
+0.08%-0.60%+2.15%+37.48%150B
Average -1.10%+0.44%+4.58%+42.34% 296.78B
Weighted average by Cap. -0.40%+1.24%+14.85%+87.99%
See all sector performances

Financials

2024 *2025 *
Net sales 692M 658M 613M 546M 973M 58.6B 1.07B 7.62B 2.83B 24.03B 2.6B 2.54B 103B 646M 614M 572M 510M 908M 54.7B 997M 7.11B 2.64B 22.43B 2.43B 2.37B 96.55B
Net income -5.13M -4.88M -4.55M -4.05M -7.22M -435M -7.92M -56.52M -20.96M -178M -19.28M -18.85M -767M 55.47M 52.77M 49.15M 43.81M 78.03M 4.7B 85.66M 611M 227M 1.93B 208M 204M 8.29B
Net Debt 117M 112M 104M 92.58M 165M 9.93B 181M 1.29B 479M 4.07B 440M 431M 17.53B -45.18M -42.98M -40.03M -35.68M -63.55M -3.83B -69.77M -498M -185M -1.57B -170M -166M -6.75B
More financial data * Estimated data
Logo Pacira BioSciences, Inc.
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
Employees
712
More about the company
Date Price Change Volume
24-12-04 19.09 $ +14.45% 1,655,537
24-12-03 16.68 $ -6.34% 1,419,812
24-12-02 17.81 $ +5.32% 589,191
24-11-29 16.91 $ +1.62% 296,431
24-11-27 16.64 $ -0.83% 487,708

Delayed Quote Nasdaq, December 03, 2024 at 04:00 pm EST

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B-
surperformance-ratings-light-chart PACIRA-BIOSCIENCES-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
16.68USD
Average target price
18.00USD
Spread / Average Target
+7.91%
Consensus

Quarterly revenue - Rate of surprise

Exceptional Extension | BLACK FRIDAY -40% : Unlock Tomorrow's Top Investments with Our Exclusive Subscriber-Only Tools!
d
:
:
BENEFIT NOW